Zhengye Biotechnology Holding Limited
ZYBT$2.36
+$1.08 (84.38%)+84.38%
After HoursLoading chart...
IndexN/A
Market Cap0.11B
Enterprise Value0.41B
Income$0.01B
Sales$0.19B
EmployeesN/A
P/E-10.73
P/S3.27
P/B1.52
P/C541.63
EV/EBITDA-9.54
EV/SalesN/A
EPS (ttm)-0.22
EarningsN/A
Gross Margin20.51%
Oper. Margin-58.66%
Profit Margin-59.97%
Volume71.02M
Shs Outstand0.05B
Change84.38%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $186.36M | $211.65M | $260.27M | $214.07M |
| Cost of Revenue | $95.06M | $81.80M | $106.75M | $88.67M |
| Gross Profit | $91.30M | $129.85M | $153.52M | $125.39M |
| Gross Margin | 48.99% | 61.35% | 58.98% | 58.58% |
| Operating Expenses | $74.86M | $84.87M | $87.69M | $73.01M |
| Operating Income | $16.44M | $44.99M | $65.83M | $52.38M |
| Operating Margin | 8.82% | 21.25% | 25.29% | 24.47% |
| Net Income | $11.31M | $31.46M | $46.73M | $38.96M |
| Net Margin | 6.07% | 14.86% | 17.96% | 18.20% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activityglobenewswire.com Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyglobenewswire.com Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyglobenewswire.com Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Resultsprnewswire.com Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structureglobenewswire.com Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Declines By 36.7%defenseworld.net Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholdersglobenewswire.com Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Resultsprnewswire.com
Show 6 more stories
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-Fglobenewswire.com Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Optionglobenewswire.com U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipelineseekingalpha.com Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offeringglobenewswire.com Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offeringglobenewswire.com Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPOseekingalpha.com
Insider Trading
No insider trades found for ZYBT.
Company
About the company
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Discover more
You may be interested in